Dr.Max made a net profit of CZK 762 mil in 2022, up 31.7% compared to the previous year. Historically, between 2013 and 2022, the company's net profit reached a high of CZK 828 mil in 2014 and a low of CZK -187 mil in 2015.
The result implies a return on equity of 13.6% and a return on invested capital of 6.32% in 2022. That is compared to an average of 10.6% and 4.57% over the last five years.
The company has been operating with average EBITDA margin of 6.17% in the last 5 years and an average net margin of 2.22%.
Since 2017, the firm's net profit increased by 476% or an average of 41.9% a year.
You can see all the company’s data at Dr.Max profile, or you can download a report on the company in the report section.
Helgi Library 
